Call for Abstracts for DPL XXXVII Is Now Open!


The American Society for Pharmacy Law (ASPL) is an organization of attorneys, pharmacists, pharmacist-attorneys and students of pharmacy or law who are interested in the law as it applies to pharmacy, pharmacists, wholesalers, manufacturers, state and federal government and other interested parties.

ASPL is a non-profit which encourages diversity & inclusion with the Society, regardless of differing backgrounds, perspectives, experiences, orientations, origins, and practice settings. The Society embraces participation and diversity as it leads to advancing our purpose: 

  • Furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues;
  • Communicating accurate legal educational information; and
  • Providing educational opportunities for pharmacists, attorneys, and others who are interested in pharmacy law

Latest News

ND Federal Judge Blocks ND 340B Law

A judge from the US District Court for the District of North Dakota blocked 340B law ND HB 1473, entering summary judgement in favor of AbbVie and PhRMA’s suits against the law.

The Court granted AbbVie’s motion for summary judgment re: the law violating the Dormant Commerce Clause, and PhRMA’s motion for summary judgment re: field preemption with the 340B statute and violation of the Commerce Clause. The Court declared H.B. 1473 unconstitutional and that it violates the Supremacy Clause and the Commerce Clause. The Court permanently enjoined and restrained North Dakota and its agents from enforcing H.B. 1473 against AbbVie; Allergan, Inc.; Durata Therapeutics, Inc; AbbVie Products LLC; Pharmacyclics LLC; Allergan Sales, LLC; and PhRMA’s members and members’ affiliates, officers, agents, representatives, or contractors.

[Order on Motions. AbbVie v. Wrigley; AstraZeneca v. Wrigley; PhRMA v. Wrigley. Cases 1:25-cv-00081; 1:25-cv-00082; 1:25-cv-00204. US Dist Ct ND. 27 Apr 2026.]